Agree that announcement is somewhat disappointing,
However there are some positives :-
Clarification that (CE Certification) for (Pancreatic Cancer Indication)
Should be granted by (BSI) after the (Stage-1, 20 Patient Safety Assessment) is completed
Data from (Stage-1) is expected to be available before the end of (September, 2017)
(7 months from now)
Once (BSI) are satisfied with (Safety Assessment)
(CE Mark) should be granted before the end of (2017)
(10 months from now)
So the positives are :-
1) If your a long-term investor,
Provides a possible (10 month) window to accumulate,
Or average down at probable lower shareprices
2) Possible less dilution,
Due to (19,000,000 Options @ 5 cents) (Expiring 3/06/2017)
Held by (Martin Rogers) who resigned in 2016, possibly not being exercised
OSL Price at posting:
9.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)